3.11. bacterial prostatitis. 3.11.1. introduction bacterial prostatitis clinical condition caused bacterial pathogens. recommended urologists use classification suggested national institute diabetes, digestive kidney diseases (niddk) national institutes health (nih), bacterial prostatitis, confirmed suspected infection, distinguished chronic pelvic pain syndrome (cpps) (table 9) [346-348]. table 9: classification prostatitis cpps according niddk/nih [346-348] typename descriptioniacute bacterial prostatitis (abp)iichronic bacterial prostatitis (cbp)iiichronic non-bacterial prostatitis – cppsiiiainflammatory cpps (white cells semen/eps/vb3)iiibnon-inflammatory cpps (no white cells semen/eps/vb3)ivasymptomatic inflammatory prostatitis (histological prostatitis) cpps = chronic pelvic pain syndrome; eps = expressed prostatic secretion; vb3 = voided bladder urinespecimen 3 (urine following prostatic massage). 3.11.2. evidence summary systematic literature search 1980 june 2017 performed. one systematic review , six rcts [350-355], two narrative reviews , one prospective cohort study , two prospective cross-sectional studies , one retrospective cohort study , selected 856 references. retrospective study , investigated potential role unusual pathogens prostatitis syndrome 1,442 patients four-year period. infectious aetiology determined 74.2% patients; c. trachomatis, t. vaginalis u. urealyticum infections found 37.2%, 10.5% 5% patients, respectively whilst e. coli infection found 6.6% cases. cross sectional studies confirmed validity meares stamey test determine bacterial strain targeted antibiotic therapies . evidence levels good, particular regarding information atypical strains, epidemiology antibiotic treatments. systematic review antimicrobial therapy cbp compared multiple antibiotic regimens eighteen selected studies enrolling total 2,196 patients. role fluoroquinolones first line agents confirmed significant differences levofloxacin, ciprofloxacin prulifloxacin terms microbiological eradication, clinical efficacy adverse events. efficacy macrolides tetracyclines atypical pathogens confirmed. randomised controlled trials combined treatments indicated combination plants/herbal extracts pde5is antibiotics may improve quality life symptoms patients cbp; however, number enrolled patients inadequate obtain definitive conclusions. review treatment bacterial prostatitis indicated treatment cbp hampered lack active antibiotic transport mechanism infected prostate tissue fluids. review underlined potential effect different compounds treatment abp cbp basis 40 studies topic. one rct compared effects two different metronidazole regimens treatment cbp caused t. vaginalis . metronidazole 500 mg three times daily fourteen days found efficient micro-organism eradication 93.3% patients clinical failure 3.33% cases. evidence question addressed was: men niddk/nih category ii prostatitis best antimicrobial treatment strategy clinical resolution eradication causative pathogen? 3.11.3. epidemiology, aetiology pathogenesis prostatitis common diagnosis, less 10% cases proven bacterial infection . enterobacterales, especially e. coli, predominant pathogens abp . cbp, spectrum species wider may include atypical micro-organisms . patients immune deficiency hiv infection, prostatitis may caused fastidious pathogens, m. tuberculosis, candida spp. rare pathogens, coccidioides immitis, blastomyces dermatitidis, histoplasma capsulatum . significance identified intracellular bacteria, c. trachomatis, uncertain ; however, two studies highlighted possible role causative pathogen cbp . 3.11.4. diagnostic evaluation 3.11.4.1. history symptoms acute bacterial prostatitis usually presents abruptly voiding symptoms distressing poorly localised pain. often associated malaise fever. transrectal prostate biopsy increases risk abp despite antibiotic prophylaxis antiseptic prevention procedures . chronic bacterial prostatitis defined symptoms persist least three months [367-369]. predominant symptoms pain various locations including perineum, scrotum, penis inner part leg well luts [346-348]. 3.11.4.2. symptom questionnaires cbp symptoms appear strong basis use classification parameter . prostatitis symptom questionnaires therefore developed assess severity response therapy . include validated chronic prostatitis symptom index (cpsi); however, usefulness clinical practice uncertain . 3.11.4.3. clinical findings abp, prostate may swollen tender dre. prostatic massage avoided induce bacteraemia sepsis. urine dipstick testing nitrite leukocytes positive predictive value 95% negative predictive value 70% . blood culture complete blood count useful abp. imaging studies detect suspected prostatic abscess . case longer lasting symptoms cpps well urogenital anorectal disorders must taken consideration. symptoms cbp cpps mask prostate tuberculosis. pyospermia hematospermia men endemic regions history tuberculosis trigger investigation urogenital tuberculosis. 3.11.4.4. urine cultures expressed prostatic secretion important investigation evaluation patient abp mid-stream urine culture . cbp, quantitative bacteriological localisation cultures microscopy segmented urine expressed prostatic secretion (eps), described meares stamey , still important investigations categorise clinical prostatitis . accurate microbiological analysis samples meares stamey test may also provide useful information presence atypical pathogens c. trachomatis, t. vaginalis u. urealiticum . two-glass test shown offer similar diagnostic sensitivity four-glass test . 3.11.4.5. prostate biopsy prostate biopsies cannot recommended routine work-up advisable patients untreated bacterial prostatitis due increased risk sepsis. 3.11.4.6. tests transrectal us may reveal endoprostatic abscesses, calcification prostate, dilatation seminal vesicles; however, unreliable diagnostic tool prostatitis . 3.11.4.7. additional investigations 3.11.4.7.1. ejaculate analysis performing ejaculated semen culture improves diagnostic utility four-glass test ; however, semen cultures often positive eps cultures men non-bacterial prostatitis . bladder outflow urethral obstruction always considered ruled uroflowmetry, retrograde urethrography, endoscopy. 3.11.4.7.2. first-void urine sample first-void urine preferred specimen diagnosis urogenital c. trachomatis infection men naats, since non-invasive yet allows detection infected epithelial cells associated c. trachomatis particles . 3.11.4.7.3. prostate specific antigen (psa) prostate specific antigen increased 60% 20% men abp cbp, respectively . psa level decreases antibiotic therapy (which occurs approximately 40% patients) correlates clinical microbiological improvement . measurement free total psa adds practical diagnostic information prostatitis . 3.11.4.8. summary evidence recommendations diagnosis bacterial prostatitis summary evidenceleurine dipstick testing nitrite leukocytes positive predictive value 95% negative predictive value 70% patients abp.3the four-glass meares stamey test optimum test diagnosis cbp. two-glass test shown offer similar diagnostic sensitivity comparison study.2bfirst-void urine preferred specimen diagnosis urogenital c. trachomatis infection men naats.2btransrectal ultrasound unreliable cannot used diagnostic tool prostatitis.3semen culture sensitivity reported approximately 50%; therefore, routinely part diagnostic assessment cbp.3prostate specific antigen levels may elevated active prostatitis; therefore, psa testing avoided offers practical diagnostic information prostatitis.3 recommendationsstrength ratingdo perform prostatic massage acute bacterial prostatitis (abp).strongtake mid-stream urine dipstick check nitrite leukocytes patients clinical suspicion abp.weaktake mid-stream urine culture patients abp symptoms guide diagnosis tailor antibiotic treatment.weaktake blood culture total blood count patients presenting abp.weakperform accurate microbiological evaluation atypical pathogens chlamydia trachomatis mycoplasmata patients chronic bacterial prostatitis (cbp).weakperform meares stamey 2- 4-glass test patients cbp.strongperform transrectal ultrasound selected cases rule presence prostatic abscess.weakdo routinely perform microbiological analysis ejaculate alone diagnose cbp.weak 3.11.5. disease management 3.11.5.1. antimicrobials antimicrobials life-saving abp recommended cbp. culture-guided antibiotic treatments optimum standard; however, empirical therapies considered patients abp. abp parenteral administration high doses bactericidal antimicrobials, broad-spectrum penicillins, third-generation cephalosporin fluoroquinolones, recommended . initial therapy, antimicrobials may combined aminoglycoside [362-371,378-382]. ancillary measures include adequate fluid intake urine drainage . normalisation infection parameters, oral therapy substituted continued total two four weeks . fluoroquinolones, despite high resistance rates uropathogens, recommended first-line agents empirical treatment cbp favourable pharmacokinetic properties , generally good safety profile antibacterial activity gram-negative pathogens including p. aeruginosa c. trachomatis . however, increasing bacterial resistance concern. azithromycin doxycycline active atypical pathogens c. trachomatis genital mycoplasmata . levofloxacin demonstrate significant clearance c. trachomatis patients cbp . metronidazole treatment indicated patients t. vaginalis infections . duration fluoroquinolone treatment must least fourteen days azithromycin doxycycline treatments extended least three four weeks . cbp antimicrobials given four six weeks initial diagnosis . intracellular bacteria detected macrolides tetracyclines given . 3.11.5.2. intraprostatic injection antimicrobials treatment evaluated controlled trials considered . 3.11.5.3. combined treatments combination fluoroquinolones various herbal extracts may attenuate clinical symptoms without increasing rate adverse events . however, combination fluoroquinolones vardenafil improve microbiological eradication rates attenuated pain voiding symptoms comparison fluoroquinolone treatment alone . 3.11.5.4. drainage surgery approximately 10% men abp experience urinary retention managed urethral suprapubic catheterisation. however, recent evidence suggests suprapubic catheterisation reduce risk development cbp . case prostatic abscess, drainage conservative treatment strategies appear feasible ; however, abscess size may matter. one study, conservative treatment successful abscess cavities < 1 cm diameter, larger abscesses better treated single aspiration continuous drainage . 3.11.5.5. summary evidence recommendations disease management bacterial prostatitis summary evidencelethe treatment regimen abp based clinical experience number uncontrolled clinical studies. systemically ill patients abp, parenteral antibiotic therapy preferable. normalisation infection parameters, oral therapy substituted continued total two four weeks.3the role fluoroquinolones first-line agents antimicrobial therapy cbp confirmed systematic review, significant differences levofloxacin, ciprofloxacin prulifloxacin terms microbiological eradication, clinical efficacy adverse events.1ametronidazole 500 mg three times daily fourteen days found efficient eradication 93.3% patients t. vaginalis cbp.1bin patients cbp caused obligate intracellular pathogens, macrolides showed higher microbiological clinical cure rates compared fluoroquinolones.1aclinicians consider local drug-resistance patterns choosing antibiotics.3 recommendationsstrength ratingacute bacterial prostatitistreat acute bacterial prostatitis according recommendations complicated utis (see section 3.7.5).strongchronic bacterial prostatitis (cbp)prescribe fluoroquinolone (e.g. ciprofloxacin, levofloxacin) first-line treatment cbp.strongprescribe macrolide (e.g. azithromycin) tetracycline (e.g. doxycycline) intracellular bacteria identified causative agent cbp.strongprescribe metronidazole patients t. vaginalis cbp.strong table 10: suggested regimens antimicrobial therapy chronic bacterial prostatitis antimicrobialdaily doseduration therapycommentsfluoroquinoloneoptimal oral daily dose4-6 weeksdoxycycline100 mg b.i.d10 daysonly c. trachomatis mycoplasma infectionsazithromycin500 mg daily3 weeksonly c. trachomatis infectionsmetronidazole500 mg t.i.d.14 daysonly t. vaginalis infections b.i.d = twice daily; t.i.d = three times daily. 3.11.6. follow-up asymptomatic post-treatment patients routine urinalysis and/or urine culture mandatory validated tests cure bacterial prostatitis except cessation symptoms . patients persistent symptoms repeated positive microbiological results sexually transmitted infectious pathogens, microbiological screening patient’s partner/s recommended. antibiotic treatments may repeated prolonged course, higher dosage and/or different compounds .